Evaluation of Influenza A H1N1 infection and antiviral utilization in a tertiary care hospital

Show simple item record

dc.contributor Sistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.author BELUCCI, Talita Rantin
MARRA, Alexandre R.
EDMOND, Michael B.
PINHO, Joao Renato Rebello FMUSP-HC
YOKOTA, Paula Kiyomi Onaga
MAFRA, Ana Carolina Cintra Nunes
SANTOS, Oscar Fernando Pavao dos
dc.date.issued 2018
dc.identifier.citation BMC INFECTIOUS DISEASES, v.18, article ID 579, 6p, 2018
dc.identifier.issn 1471-2334
dc.identifier.uri http://observatorio.fm.usp.br/handle/OPI/30158
dc.description.abstract Background: Influenza A H1N1 infections carry a significant mortality risk. This study describes inpatients with suspected and confirmed Influenza A H1N1 infection who were prescribed oseltamivir, the risk factors associated with infection, the association between infection and mortality, and the factors associated with in-hospital mortality in infected patients. Methods: This study was a matched case-control study of hospitalized patients who underwent real-time polymerase chain reaction testing for Influenza A H1N1 and were treated with oseltamivir from 2009 to 2015 in a tertiary care hospital. Cases (patients with positive Influenza A H1N1 testing) were matched 1:1 to controls (patients with negative test results). Results: A total of 1405 inpatients who underwent PCR testing and received treatment with oseltamivir were identified in our study and 157 patients confirmed Influenza A H1N1. Almost one third of patients with Influenza A H1N1 were diagnosed in the pandemic period. There was no difference in mortality between cases and controls. Immunocompromised status, requirement of vasoactive drugs, mechanical ventilation, acute hemodialysis, albumin administration, surgical procedures and thoracic procedures and length of stay were associated with increased risk of death in Influenza A H1N1 infected patients. Conclusions: We found no increased risk of mortality for patients with proven Influenza A H1N1 when compared to similar patients without confirmed Influenza.
dc.language.iso eng
dc.publisher BMC
dc.relation.ispartof BMC Infectious Diseases
dc.rights openAccess
dc.subject Influenza a H1N1; Oseltamivir; Hospitalized patients
dc.subject.other package
dc.title Evaluation of Influenza A H1N1 infection and antiviral utilization in a tertiary care hospital
dc.type article
dc.rights.holder Copyright BMC
dc.description.group LIM/03
dc.identifier.doi 10.1186/s12879-018-3492-z
dc.identifier.pmid 30445924
dc.type.category original article
dc.type.version publishedVersion
hcfmusp.author PINHO, Joao Renato Rebello:HC:ICHC
hcfmusp.author.external · BELUCCI, Talita Rantin:Hosp Israelita Albert Einstein, Sao Paulo, Brazil; Hosp Israelita Albert Einstein, Div Med Practice, Ave Albert Einstein 627 Bloco A1,1 Andar, BR-05651901 Sao Paulo, Brazil
· MARRA, Alexandre R.:Hosp Israelita Albert Einstein, Div Med Practice, Ave Albert Einstein 627 Bloco A1,1 Andar, BR-05651901 Sao Paulo, Brazil; Univ Iowa Hosp & Clin, Off Clin Qual Safety & Performance Improvement, Iowa City, IA 52242 USA
· EDMOND, Michael B.:Univ Iowa Hosp & Clin, Off Clin Qual Safety & Performance Improvement, Iowa City, IA 52242 USA; Univ Iowa, Carver Coll Med, Dept Internal Med, Div Infect Dis, Iowa City, IA USA
· YOKOTA, Paula Kiyomi Onaga:Hosp Israelita Albert Einstein, Div Med Practice, Ave Albert Einstein 627 Bloco A1,1 Andar, BR-05651901 Sao Paulo, Brazil
· MAFRA, Ana Carolina Cintra Nunes:Hosp Israelita Albert Einstein, Inst Israelita Ensino & Pesquisa Albert Einstein, Stat Dept, Sao Paulo, Brazil; Hosp Israelita Albert Einstein, Nucleo Indicadores & Sistemas Informacoes, Sao Paulo, Brazil
· SANTOS, Oscar Fernando Pavao dos:Hosp Israelita Albert Einstein, Div Med Practice, Ave Albert Einstein 627 Bloco A1,1 Andar, BR-05651901 Sao Paulo, Brazil
hcfmusp.origem.id WOS:000450531100004
hcfmusp.origem.id 2-s2.0-85056723837
hcfmusp.publisher.city LONDON
hcfmusp.publisher.country ENGLAND
hcfmusp.relation.reference · Alvarez-Lerma F, 2017, J HOSP INFECT, V95, P200, DOI 10.1016/j.jhin.2016.12.017
· Bautista E, 2010, NEW ENGL J MED, V362, P1708, DOI 10.1056/NEJMra1000449
· Coleman BL, 2017, ANTIVIR RES, V140, P158, DOI 10.1016/j.antiviral.2017.01.025
· Garnacho-Montero J, 2018, J CRIT CARE, V48, P172, DOI 10.1016/j.jcrc.2018.08.017
· Halekoh U, 2006, J STAT SOFTW, V15, P1
· McGeer AJ, 2009, CLIN INFECT DIS, V48, pS14, DOI 10.1086/591852
· Ministerio da Saude. Secretaria de Vigilancia em Saude, 2013, INFL MON AT SEM EP
· Ministerio da Saude. Secretaria de Vigilancia em Saude, 2015, INFL MON AT SEM EP
· Ministerio da Saude. Secretaria de Vigilancia em Saude, 2014, INFL MON AT SEM EP
· Pires EM, 2014, HOSP ISRAELITA A EIN
· Rewar S, 2015, ANN GLOB HEALTH, V81, P645, DOI 10.1016/j.aogh.2015.08.014
· Rodriguez-Rieiro C, 2012, HUM VACC IMMUNOTHER, V8, P443, DOI 10.4161/hv.18911
· Sekhon JS, 2011, J STAT SOFTW, V42, P1
· Shah NS, 2015, INFECT CONT HOSP EP, V36, P1251, DOI 10.1017/ice.2015.170
· Zazueta-Garcia R, 2014, J INFECT DEV COUNTR, V8, P331, DOI 10.3855/jidc.3726
dc.description.index MEDLINE
hcfmusp.citation.scopus 0
hcfmusp.citation.wos 0
hcfmusp.affiliation.country Brasil
hcfmusp.affiliation.country Estados Unidos


Files in this item

This item appears in the following Collection(s)

Show simple item record

Search DSpace



Browse

My Account

Statistics